IN8bio (INAB) Competitors $2.00 -0.10 (-4.76%) Closing price 04:00 PM EasternExtended Trading$2.01 +0.01 (+0.30%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INAB vs. ESLA, JATT, SCYX, OKUR, SNTI, XLO, RANI, MURA, RENB, and PYRGFShould you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include Estrella Immunopharma (ESLA), JATT Acquisition (JATT), SCYNEXIS (SCYX), OnKure Therapeutics (OKUR), Senti Biosciences (SNTI), Xilio Therapeutics (XLO), Rani Therapeutics (RANI), Mural Oncology (MURA), Renovaro (RENB), and PyroGenesis Canada (PYRGF). These companies are all part of the "pharmaceutical products" industry. IN8bio vs. Its Competitors Estrella Immunopharma JATT Acquisition SCYNEXIS OnKure Therapeutics Senti Biosciences Xilio Therapeutics Rani Therapeutics Mural Oncology Renovaro PyroGenesis Canada IN8bio (NASDAQ:INAB) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership. Which has higher earnings & valuation, INAB or ESLA? Estrella Immunopharma is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIN8bioN/AN/A-$30.44M-$9.11-0.22Estrella ImmunopharmaN/AN/AN/A-$0.26-4.10 Is INAB or ESLA more profitable? IN8bio's return on equity of -184.97% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets IN8bioN/A -184.97% -126.75% Estrella Immunopharma N/A -1,132.38%-358.54% Which has more volatility and risk, INAB or ESLA? IN8bio has a beta of 0.02, meaning that its share price is 98% less volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Do institutionals & insiders hold more shares of INAB or ESLA? 92.1% of IN8bio shares are owned by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are owned by institutional investors. 9.5% of IN8bio shares are owned by company insiders. Comparatively, 55.1% of Estrella Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts prefer INAB or ESLA? IN8bio presently has a consensus price target of $180.00, indicating a potential upside of 8,900.00%. Estrella Immunopharma has a consensus price target of $16.00, indicating a potential upside of 1,402.35%. Given IN8bio's higher possible upside, analysts clearly believe IN8bio is more favorable than Estrella Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor INAB or ESLA? In the previous week, IN8bio and IN8bio both had 2 articles in the media. IN8bio's average media sentiment score of 1.45 beat Estrella Immunopharma's score of 0.95 indicating that IN8bio is being referred to more favorably in the media. Company Overall Sentiment IN8bio Positive Estrella Immunopharma Positive SummaryIN8bio beats Estrella Immunopharma on 6 of the 9 factors compared between the two stocks. Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INAB vs. The Competition Export to ExcelMetricIN8bioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.08M$3.10B$5.75B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-0.2221.3874.9226.41Price / SalesN/A243.79457.0188.61Price / CashN/A44.4425.8129.91Price / Book0.339.6413.256.28Net Income-$30.44M-$53.20M$3.29B$270.38M7 Day Performance-7.41%0.44%0.47%2.70%1 Month Performance-15.61%4.26%4.59%5.99%1 Year Performance-78.94%9.43%73.41%25.94% IN8bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INABIN8bio3.4931 of 5 stars$2.00-4.8%$180.00+8,900.0%-77.9%$9.08MN/A-0.2220Positive NewsShort Interest ↓ESLAEstrella Immunopharma2.6578 of 5 stars$1.00-4.8%$16.00+1,500.0%-2.8%$38.92MN/A-3.85N/AGap UpHigh Trading VolumeJATTJATT AcquisitionN/A$2.20+6.3%N/A-45.9%$37.95MN/A0.003High Trading VolumeSCYXSCYNEXIS1.6292 of 5 stars$0.92+3.0%N/A-23.3%$37.31M$3.26M-2.2960OKUROnKure Therapeutics3.7456 of 5 stars$2.63-4.4%$32.33+1,129.4%N/A$37.21MN/A-0.55N/ASNTISenti Biosciences3.3708 of 5 stars$1.32-5.0%$8.50+543.9%-56.0%$36.36M$2.56M-0.154Positive NewsShort Interest ↓XLOXilio Therapeutics2.7651 of 5 stars$0.70-0.6%$3.00+331.2%-10.2%$36.27M$6.34M-0.9270RANIRani Therapeutics3.1934 of 5 stars$0.50-0.4%$7.33+1,366.7%-78.9%$36.09M$1.03M-0.55110Positive NewsShort Interest ↓Gap DownMURAMural Oncology2.5393 of 5 stars$2.07flat$12.00+479.7%-36.8%$35.86MN/A-0.24119Short Interest ↑RENBRenovaro0.8646 of 5 stars$0.19-8.9%N/A-69.7%$35.54MN/A-0.2420Gap UpHigh Trading VolumePYRGFPyroGenesis CanadaN/A$0.19-1.5%N/A-67.9%$35.11M$9.14M-3.1290High Trading Volume Related Companies and Tools Related Companies ESLA Competitors JATT Competitors SCYX Competitors OKUR Competitors SNTI Competitors XLO Competitors RANI Competitors MURA Competitors RENB Competitors PYRGF Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INAB) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
